Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Mutations in codon 317 after treatment with imatinib and dasatinib have been reported. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20, including 12/99 (12%) with mutation after imatinib failure, and 8/16 (50%)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Jabbour, Elias, Kantarjian, Hagop M., Jones, Dan, Reddy, Neeli, O'Brien, Susan, Garcia-Manero, Guillermo, Burger, Jan, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4186640/
https://ncbi.nlm.nih.gov/pubmed/18818391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-04-149948
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares